Replies to post #191446 on Biotech Values

[poorgradstudent]

FGEN / ENTA:

And what number do you plan to use for "Y" that makes this easier?

What I was trying to convey is that, from my conversations, the factors that will go into roxa treatment (and duration) in an end-stage renal disease patient are more nuanced than treating someone with an HCV antiviral. Duration of treatment and the ways docs will optimally work roxa into their treatment are more complicated (and less predictable imo) than for the antivirals.

Easier was the wrong word. Both are challenging, but one is less so imo.